ACRX RSI Chart
Last 7 days
-3.8%
Last 90 days
7.5%
Trailing 12 Months
62.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 89.6M | 0 | 0 | 0 |
2022 | 23.1M | 43.4M | 63.7M | 84.1M |
2021 | 5.5M | 3.1M | 3.6M | 2.8M |
2020 | 2.2M | 4.2M | 5.0M | 5.4M |
2019 | 2.4M | 2.6M | 2.8M | 2.5M |
2018 | 5.2M | 3.4M | 2.3M | 2.2M |
2017 | 17.4M | 15.6M | 13.7M | 8.0M |
2016 | 22.1M | 24.7M | 12.7M | 17.4M |
2015 | 8.7M | 12.2M | 15.8M | 19.3M |
2014 | 23.4M | 17.4M | 11.3M | 5.2M |
2013 | 3.0M | 3.2M | 3.6M | 29.5M |
2012 | 1.4M | 1.7M | 2.1M | 2.4M |
2011 | 0 | 0 | 0 | 1.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 13, 2023 | angotti vincent j. | bought | 7,268 | 0.7268 | 10,000 | chief executive officer |
Oct 10, 2023 | hoffman stephen j | acquired | - | - | 581 | - |
Oct 10, 2023 | afable richard | acquired | - | - | 581 | - |
Oct 10, 2023 | adams adrian | acquired | - | - | 581 | - |
Oct 10, 2023 | broadfoot jill marie | acquired | - | - | 581 | - |
Oct 10, 2023 | rosen howard b | acquired | - | - | 581 | - |
Oct 10, 2023 | wan mark a | acquired | - | - | 581 | - |
Oct 10, 2023 | bozilenko marina | acquired | - | - | 581 | - |
Sep 11, 2023 | angotti vincent j. | bought | 7,950 | 0.795 | 10,000 | chief executive officer |
Aug 25, 2023 | palmer pamela p | sold | -8,104 | 1.089 | -7,442 | chief medical officer |
Which funds bought or sold ACRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 30, 2024 | Turtle Creek Wealth Advisors, LLC | added | 204 | 56,372 | 73,645 | 0.02% |
Apr 30, 2024 | MACROVIEW INVESTMENT MANAGEMENT LLC | unchanged | - | 15.00 | 52.00 | -% |
Apr 29, 2024 | Silicon Valley Capital Partners | unchanged | - | 40.00 | 141 | -% |
Apr 25, 2024 | Rosalind Advisors, Inc. | unchanged | - | 223,895 | 781,735 | 0.73% |
Apr 23, 2024 | Values First Advisors, Inc. | reduced | -16.14 | 17,417 | 116,817 | 0.07% |
Apr 23, 2024 | Global Retirement Partners, LLC | added | 217 | 57.00 | 75.00 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 3.09 | 30,531 | 130,170 | -% |
Feb 26, 2024 | Virtu Financial LLC | added | 156 | 33,000 | 48,000 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | reduced | -21.24 | -18.00 | 8,982 | -% |
Unveiling AcelRx Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to AcelRx Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 359.2B | 85.6B | 9.34 | 4.19 | ||||
MRK | 323.0B | 61.4B | 140.05 | 5.26 | ||||
AMGN | 166.9B | 29.5B | 44.36 | 5.65 | ||||
PFE | 157.1B | 46.5B | -113.14 | 3.37 | ||||
GILD | 80.7B | 27.1B | 14.25 | 2.98 | ||||
TEVA | 15.6B | 15.8B | -27.18 | 0.99 | ||||
MID-CAP | ||||||||
PRGO | 4.4B | 4.7B | -349.99 | 0.95 | ||||
ALKS | 4.1B | 1.7B | 9.38 | 2.36 | ||||
BHC | 2.9B | 9.0B | -6.3 | 0.32 | ||||
AMPH | 2.0B | 644.4M | 14.84 | 3.17 | ||||
SMALL-CAP | ||||||||
TLRY | 1.6B | 743.2M | -4.6 | 2.18 | ||||
TXMD | 22.0M | 1.3M | -2.14 | 16.92 | ||||
ACRX | 17.1M | - | -0.93 | 0.22 | ||||
AGRX | 2.5M | 19.6M | -0.17 | 0.13 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
AcelRx Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | -100.0% | - | 5,511,000 | - | - | 84,052,000 | 42,027,000 | 2,000 | 1,862,000 | 443,000 | 511,000 | 738,000 | 1,368,000 | 2,924,000 | 386,000 | 294,000 | 608,000 | 941,000 | 627,000 | 613,000 | 377,000 | 818,000 |
Costs and Expenses | -14.3% | 4,564,000 | 5,328,000 | 5,886,000 | 4,523,000 | 9,955,000 | 4,936,000 | -12,112,000 | 10,495,000 | 10,458,000 | 9,653,000 | 9,982,000 | 10,405,000 | 9,758,000 | 16,234,000 | 15,467,000 | 14,142,000 | 14,302,000 | 12,583,000 | 11,590,000 | 9,705,000 | 7,971,000 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11,590,000 | 9,705,000 | 7,971,000 |
S&GA Expenses | -34.7% | 2,795,000 | 4,281,000 | 5,227,000 | 3,724,000 | 3,960,000 | 4,100,000 | -9,490,000 | 8,640,000 | 8,694,000 | 7,644,000 | 7,846,000 | 7,598,000 | 7,575,000 | 13,311,000 | 12,786,000 | 10,936,000 | 11,329,000 | 9,976,000 | 7,648,000 | 5,188,000 | 3,944,000 |
R&D Expenses | 69.0% | 1,769,000 | 1,047,000 | 612,000 | 799,000 | 1,094,000 | 836,000 | -674,000 | 1,416,000 | 724,000 | 969,000 | 836,000 | 956,000 | 813,000 | 1,412,000 | 1,063,000 | 1,058,000 | 1,163,000 | 1,377,000 | 2,704,000 | 3,642,000 | 3,278,000 |
EBITDA Margin | -100.0% | - | 0.73 | 0.74 | -0.22 | -0.32 | -0.57 | -4.61 | -10.10 | -11.64 | -6.40 | -6.50 | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | -100.0% | - | 119,000 | 188,000 | 245,000 | 293,000 | 390,000 | 369,000 | 538,000 | 614,000 | 672,000 | 754,000 | 824,000 | 872,000 | 855,000 | 831,000 | 828,000 | 500,000 | 376,000 | 459,000 | 529,000 | 586,000 |
Income Taxes | -Infinity% | -5,000 | - | -1,000 | 11,000 | 3,000 | - | - | - | 5,000 | - | - | - | 4,000 | - | - | - | 3,000 | - | - | - | 2,000 |
Earnings Before Taxes | - | - | - | 3,885,000 | -6,739,000 | 70,666,000 | - | 10,030,000 | -8,375,000 | -9,846,000 | - | -8,918,000 | -8,930,000 | -6,602,000 | - | -14,423,000 | -12,731,000 | -12,409,000 | - | -12,558,000 | -12,458,000 | -10,539,000 |
EBT Margin | -100.0% | - | 0.70 | 0.70 | -0.27 | -0.39 | -0.74 | -6.08 | -11.36 | -13.19 | -7.29 | -7.45 | - | - | - | - | - | - | - | - | - | - |
Net Income | 44.6% | -4,517,000 | -8,152,000 | -7,484,000 | -6,750,000 | 70,663,000 | -8,674,000 | -7,917,000 | -8,375,000 | -9,851,000 | -8,956,000 | -8,918,000 | -8,930,000 | -6,606,000 | -15,925,000 | -14,423,000 | -12,731,000 | -12,412,000 | -13,674,000 | -12,558,000 | -12,458,000 | -10,541,000 |
Net Income Margin | -100.0% | - | 0.57 | 0.57 | 0.74 | 1.05 | -1.51 | -12.46 | -10.16 | -11.98 | -6.03 | -7.46 | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | 26.2% | -3,949,000 | -5,350,000 | -5,461,000 | -5,396,000 | -8,815,000 | -9,023,000 | -8,032,000 | -4,127,000 | -9,938,000 | -9,732,000 | -7,958,000 | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -12.3% | 20.00 | 23.00 | 18.00 | 26.00 | 47.00 | 48.00 | 56.00 | 72.00 | 78.00 | 72.00 | 80.00 | 87.00 | 66.00 | 66.00 | 67.00 | 77.00 | 91.00 | 105 | 115 | 113 | 121 |
Current Assets | -19.9% | 12.00 | 14.00 | 9.00 | 17.00 | 25.00 | 25.00 | 32.00 | 43.00 | 50.00 | 52.00 | 59.00 | 71.00 | 47.00 | 48.00 | 49.00 | 58.00 | 72.00 | 86.00 | 97.00 | 95.00 | 108 |
Cash Equivalents | -57.3% | 6.00 | 13.00 | 7.00 | 13.00 | 15.00 | 13.00 | 15.00 | 22.00 | 8.00 | 8.00 | 21.00 | 34.00 | 22.00 | 20.00 | 22.00 | 24.00 | 15.00 | 22.00 | 65.00 | 73.00 | 88.00 |
Inventory | - | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 |
Net PPE | - | - | - | - | - | - | 11.00 | 11.00 | 16.00 | 5.00 | 16.00 | 16.00 | 16.00 | 16.00 | 14.00 | 14.00 | 15.00 | 15.00 | 14.00 | 13.00 | 12.00 | 11.00 |
Liabilities | 27.0% | 6.00 | 5.00 | 7.00 | 12.00 | 26.00 | 21.00 | 23.00 | 110 | 114 | 115 | 116 | 115 | 122 | 124 | 128 | 133 | 133 | 133 | 134 | 121 | 116 |
Current Liabilities | 26.2% | 5.00 | 4.00 | 4.00 | 9.00 | 14.00 | 16.00 | 18.00 | 17.00 | 19.00 | 17.00 | 15.00 | 16.00 | 18.00 | 17.00 | 16.00 | 16.00 | 14.00 | 11.00 | 8.00 | 19.00 | 16.00 |
Long Term Debt | - | - | - | - | - | - | - | - | 3.00 | 5.00 | 7.00 | 9.00 | 11.00 | 13.00 | 15.00 | 17.00 | 19.00 | 21.00 | 22.00 | 24.00 | - | 3.00 |
LT Debt, Current | - | - | - | - | 3.00 | 5.00 | 8.00 | 10.00 | 9.00 | 8.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 7.00 | 5.00 | 2.00 | - | 10.00 | 9.00 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | 3.00 | 5.00 | 7.00 | 9.00 | 11.00 | 13.00 | 15.00 | 17.00 | 19.00 | 21.00 | 22.00 | 24.00 | - | 3.00 |
Shareholder's Equity | -23.0% | 14.00 | 18.00 | 10.00 | 14.00 | 22.00 | 27.00 | 33.00 | - | -35.89 | - | - | - | - | - | - | - | - | - | - | - | 4.00 |
Retained Earnings | -1.0% | -444 | -439 | -438 | -433 | -425 | -418 | -411 | -482 | -473 | -465 | -457 | -447 | -438 | -429 | -420 | -414 | -398 | -383 | -370 | -358 | -345 |
Additional Paid-In Capital | 0.1% | 458 | 458 | 449 | 448 | 448 | 446 | 445 | 444 | 438 | 423 | 421 | 420 | 383 | 372 | 360 | 359 | 357 | 355 | 352 | 351 | 349 |
Shares Outstanding | 0.0% | 17.00 | 17.00 | 11.00 | 11.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 6.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 12.00 | - | - | - | 36.00 | - | - | - | 161 | - | - | - | 95.00 | - | - | - | 197 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -33.4% | -3,949 | -2,960 | -5,333 | -5,250 | -5,413 | -5,238 | -8,746 | -8,934 | -8,004 | -3,943 | -8,347 | -9,708 | -6,327 | -8,124 | -9,690 | -14,364 | -14,155 | -11,466 | -12,319 | -13,240 | -8,990 |
Share Based Compensation | -17.7% | 311 | 378 | 471 | 569 | 652 | 701 | 753 | 783 | 1,127 | 1,221 | 1,172 | 1,089 | 1,084 | 1,104 | 1,090 | 1,146 | 1,278 | 1,326 | 1,346 | 1,107 | 1,232 |
Cashflow From Investing | -Infinity% | -3,651 | - | 2,723 | 400 | 2,660 | 4,442 | 9,172 | 20,176 | -4,439 | -6,652 | 2,393 | -17,425 | 5,775 | -1,214 | 6,928 | 22,650 | 6,889 | -33,206 | -10,617 | 371 | -11,960 |
Cashflow From Financing | -100.8% | -68.00 | 8,939 | -3,333 | -2,072 | 5,296 | -1,637 | -2,083 | -2,083 | 11,835 | -2,461 | -2,082 | 34,222 | 7,853 | 7,522 | 665 | 916 | 1.00 | 1,550 | 14,695 | -1,794 | 51,359 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Total revenue | $ 651 | $ 0 |
us-gaap_OperatingCostsAndExpensesAbstract | ||
Research and development | 5,546 | 3,341 |
Selling, general and administrative | 11,994 | 17,011 |
Impairment of property and equipment | 0 | 4,948 |
Total operating costs and expenses | 17,540 | 25,300 |
Loss from operations | (16,889) | (25,300) |
Interest expense | (134) | (1,116) |
Interest income and other income, net | 6,736 | 366 |
Non-cash interest income on liability related to sale of future royalties | 0 | 1,136 |
Non-cash gain on extinguishment of liability related to the sale of future royalties | 0 | 84,052 |
Total other income, net | 6,602 | 84,438 |
Net income (loss) before provision for income taxes | (10,287) | 59,138 |
Provision for income taxes | 0 | (13) |
Net (loss) income from continuing operations | (10,287) | 59,125 |
Net loss from discontinued operations – See Note 3 | (8,110) | (11,370) |
Net income (loss) | (18,397) | 47,755 |
Deemed dividend related to Series A Redeemable Convertible Preferred Stock | 0 | (186) |
Income allocated to participating securities | 0 | (5,240) |
Net income (loss) attributable to Common Shareholders, basic | (18,397) | 42,329 |
Net income (loss) attributable to Common Shareholders, diluted | $ (18,397) | $ 42,342 |
us-gaap_EarningsPerShareBasicAbstract | ||
(Loss) income from continuing operations (in dollars per share) | $ (0.72) | $ 7.27 |
Loss from discontinued operations (in dollars per share) | (0.57) | (1.54) |
Net income (loss) per share of common stock, basic (in dollars per share) | (1.29) | 5.73 |
us-gaap_EarningsPerShareDilutedAbstract | ||
(Loss) income from continuing operations (in dollars per share) | (0.72) | 7.25 |
Loss from discontinued operations (in dollars per share) | (0.57) | (1.53) |
Net (loss) income per share (in dollars per share) | $ (1.29) | $ 5.72 |
Shares used in computing net (loss) income per share of common stock, basic – See Note 12 (in shares) | 14,263,744 | 7,385,348 |
Shares used in computing net (loss) income per share of common stock, diluted – See Note 12 (in shares) | 14,263,744 | 7,406,986 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 5,721 | $ 15,275 |
Restricted cash | 0 | 5,000 |
Short-term investments | 3,660 | 495 |
Prepaid expenses and other current assets | 2,175 | 1,865 |
Assets of discontinued operations | 0 | 1,931 |
Total current assets | 11,556 | 24,566 |
In-process research and development asset | 8,819 | 8,819 |
Other assets | 20 | 166 |
Assets of discontinued operations | 0 | 13,936 |
Total assets | 20,395 | 47,487 |
Current Liabilities: | ||
Accounts payable | 1,336 | 1,256 |
Accrued and other liabilities | 2,445 | 2,531 |
Long-term debt, current portion | 0 | 5,363 |
Liabilities of discontinued operations, current portion | 731 | 4,620 |
Total current liabilities | 4,512 | 13,770 |
Warrant liability | 1,778 | 7,098 |
Other long-term liabilities | 0 | 810 |
Liabilities of discontinued operations | 0 | 3,995 |
Total liabilities | 6,290 | 25,673 |
Commitments and Contingencies | ||
us-gaap_StockholdersEquityAbstract | ||
Common stock, $0.001 par value—200,000,000 shares authorized as of December 31, 2023 and 2022; 16,952,519 and 8,243,680 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 17 | 8 |
Additional paid-in capital | 458,314 | 447,635 |
Accumulated deficit | (444,226) | (425,829) |
Total stockholders’ equity | 14,105 | 21,814 |
Total Liabilities and Stockholders’ Equity | $ 20,395 | $ 47,487 |
 | Mr. Vincent J. Angotti |
---|---|
 | acelrx.com |
 | Pharmaceuticals |
 | 19 |